Krka, d. d. (FRA:KN8)

Market Cap	7.43B +52.0%
Revenue (ttm)	2.01B +5.7%
Net Income	398.80M +10.8%
EPS	13.02 +11.6%
Shares Out	n/a
PE Ratio	18.64
Forward PE	18.91
Dividend	8.25 (3.44%)
Ex-Dividend Date	Jul 22, 2025

Volume	8
Average Volume	53
Open	240.00
Previous Close	240.00
Day's Range	240.00 - 248.00
52-Week Range	159.50 - 250.00
Beta	n/a
RSI	69.65
Earnings Date	Mar 12, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, oncology, pain relief, antiinfectives for systemic use, antidiabetics, and other products. It provides non-prescription prod...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 13,107
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KN8

Financial Performance

In 2024, Krka, d. d.'s revenue was 1.91 billion, an increase of 5.71% compared to the previous year's 1.81 billion. Earnings were 356.99 million, an increase of 13.71%.